$100MSeries B, 31 March 2026
Series B to take its next-generation oral GLP-1 program into the clinic
- Amount
- $100M
- Stage
- Series B
- Announced
- 31 March 2026
- Lead
- Blue Owl Healthcare Opportunities
- Use of funds
- Series B to take its next-generation oral GLP-1 program into the clinic
- Checked
- Announced by the company
- Sources
- Ambrosia Biosciences announces $100M Series B pulse2.com
Ambrosia Biosciences announces $100M Series B pulse2.com